

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION: Frank LEENDERS, et al.

GROUP ART UNIT: 1651

SERIAL NUMBER: 10/560,317

EXAMINER: Thane E. UNDERDAHL

FILING DATE: July 13, 2006

CONFIRMATION NO.: 4625

FOR: COMBINED PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF CANCER, CONTAINING GLUTAMINASE AND ANTINEOPLASTIC ANTHRACYCLINES OR PLATINUM COMPOUNDS

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.97

Commissioner for Patents  
PO BOX 1450  
ALEXANDRIA, VA 22313-1450

Sir:

Applicant wishes to disclose the following information.

REFERENCES

Applicant wishes to make of record the document listed on the attached Form PTO/SB/08a. Copies of the listed documents are attached, where required, as are either statements of relevancy or any readily available full or partial English translations of any non-English-language documents. The listing of documents on the attached documents should not be taken as an admission that such documents are prior art.

RELATED CASES

Attached is a list of Applicant's pending applications and issued patents which may be related to the present application. Copies of the documents, where required, are attached along with Form PTO/SB/08a.

CERTIFICATION

The undersigned certifies that

each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign or international patent office in a counterpart foreign or international application for the first time (to the knowledge of the undersigned, having made reasonable inquiry) not more than three months prior to the filing of this statement.

no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign or international patent office in a counterpart foreign or international application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this statement.

BASIS FOR CONSIDERATION

This Information Disclosure Statement is filed:

without fee and within three months of the filing date of the application.

without fee and within three months of the date of entry of the U.S. national stage.

without fee and before the mailing date of a first Office Action on the merits (to the knowledge of the undersigned).


without fee and with the appropriate certification above.

without fee and with a Request for Continued Examination.

with fee and before the mailing date of any Final Office Action, Notice of Allowance or an action that otherwise closes prosecution (to the knowledge of the undersigned).

with fee, appropriate certification above, and before payment of the Issue Fee.

Respectfully submitted,  
MORRIS, MANNING & MARTIN, LLP

  
Ping Wang, M.D.  
Registration No.: 48,328

1333 H Street, NW, Suite 820  
Washington, DC 20005  
Telephone No. 202.842.0217  
Facsimile No. 202.408.5146